These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10128129)

  • 1. Pharmaceuticals and public policy: learning from the New Zealand experience.
    Davis P
    Health Policy; 1993 Aug; 24(3):259-72. PubMed ID: 10128129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The market for pharmaceuticals.
    Bergenheim K; Braun U
    Dev Health Econ Public Policy; 1998; 7():187-208. PubMed ID: 10538829
    [No Abstract]   [Full Text] [Related]  

  • 3. The Chinese medicines market: moving towards a market system?
    Huttin C
    Health Policy; 1994 Sep; 29(3):247-59. PubMed ID: 10138727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The societal value of pharmaceuticals. Balancing industrial and healthcare policy.
    Grund J
    Pharmacoeconomics; 1996 Jul; 10(1):14-22. PubMed ID: 10160467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perception, reality, and the political context of conflict of interest in university-industry relationships.
    Frankel MS
    Acad Med; 1996 Dec; 71(12):1297-304. PubMed ID: 9114887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost and utilisation of pharmaceuticals in Sweden.
    Ljungkvist MO; Andersson D; Gunnarsson B
    Health Policy; 1997 Sep; 41 Suppl():S55-69. PubMed ID: 10174474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 8. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 9. Funding arrangements for pharmaceuticals: can economic evaluation promote efficiency?
    Viney R
    Aust Health Rev; 2001; 24(2):21-4. PubMed ID: 11496466
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 11. The burgeoning science of genetics and the impact on public policy.
    Hatch OG
    J Biolaw Bus; 2004; 7(4):3-6. PubMed ID: 15675088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drug pricing scheme could politicise decisions and reduce access, says think tank.
    O'Dowd A
    BMJ; 2013 May; 346():f2965. PubMed ID: 23657194
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
    Lexchin J
    Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 15. The pharmaceutical industry as a political player.
    Abraham J
    Lancet; 2002 Nov; 360(9344):1498-502. PubMed ID: 12433532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 17. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
    Feldman R; Wang C
    N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550
    [No Abstract]   [Full Text] [Related]  

  • 18. [Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property].
    Jannuzzi AH; Vasconcellos AG; de Souza CG
    Cad Saude Publica; 2008 Jun; 24(6):1205-18. PubMed ID: 18545747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G
    Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract]   [Full Text] [Related]  

  • 20. Bangladesh national drug policy: an example for the Third World?
    Islam N
    Trop Doct; 1999 Apr; 29(2):78-80. PubMed ID: 10418296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.